Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim and Presidents and Fellows of Harvard College have established a translational research collaboration to identify and investigate novel signaling pathways and drug targets in cardiometabolic,oncology,fibrotic and infectious diseases.
Subscribe to our email newsletter
As part of the agreement, the collaboration will sponsor a variety of research projects by granting funds to support proposals selected by a joint research committee.
The funds will enable the Harvard research community to address several RNAi screening projects using specifically tailored screening systems.
The results of the funded projects will enhance knowledge in the area of innovative healthcare solutions and oncology.
Boehringer Ingelheim global research networking vice president Adrian Carter said Boehringer is pleased to sponsor the joint research programs by the distinguished scientists at Harvard in the important fields of medical need.
"We believe that this research collaboration with Harvard will help us create new medicines for a variety of important diseases that afflict our society today,” Adrian added.